Alpha Teknova, Inc. announced its financial results for the second quarter ended June 30, 2025, reporting total revenue of $10.3 million. This represents a 7% increase compared to $9.6 million in the second quarter of 2024, marking four consecutive quarters of year-over-year revenue growth.
Clinical Solutions revenue in Q2 2025 increased 32% to $2.1 million from $1.6 million in the prior-year quarter. Lab Essentials revenue grew 2% to $7.8 million compared to $7.6 million in Q2 2024.
Gross profit for the second quarter 2025 improved to $4.0 million, resulting in a gross margin of 38.7%, up from $2.8 million and 29.2% margin in Q2 2024. The net loss for the quarter was $3.6 million, or negative $0.07 per diluted share, an improvement from $5.4 million, or negative $0.13 per diluted share, in Q2 2024.
Adjusted EBITDA significantly improved to negative $0.8 million from negative $2.6 million year-over-year, and free cash outflow decreased to negative $2.3 million from negative $3.0 million. The company reaffirmed its fiscal 2025 revenue guidance of $39 million to $42 million and continues to anticipate full-year free cash outflow of less than $12 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.